Page 109 - GPD-3-3
P. 109
Gene & Protein in Disease Exploring serum inflammatory biomarkers in GBM
A
B
Figure 6. (A) Acute phase reactant pathway interaction for candidate serum inflammatory proteins, employing pre- versus post-chemoradiation therapy
(CRT) alteration data, illustrating interleukin (IL)-6 as a mediator and the potential mechanisms for serum measurements of the analyzed proteins,
particularly those identified as statistically significant for alteration or interaction. (B) Tumor microenvironment pathway interaction for candidate serum
inflammatory proteins, employing pre versus post-CRT alteration data, illustrating IL-6 as a functional unit and the potential downstream effects of the
analyzed proteins, particularly those identified as statistically significant for alteration or interaction.
this study, thus limiting comparisons. In our dataset, not possible to determine which specific isoforms are
85
two isoforms were presented: one was measured at captured in the SomaLogic® panel. However, we can
higher levels and altered with CRT, while the other was conclude that serum GFAP provides an opportunity for
consistently measured at low levels across all patients, future studies in conjunction with clinical features and
with no evident alteration with CRT. At present, it is patient outcomes.
Volume 3 Issue 3 (2024) 9 doi: 10.36922/gpd.3580
